Mabwell recently announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance from the US Food and Drug Administration (FDA) to conduct clinical studies for the treatment of Inflammatory Bowel Disease (IBD). Clinical trial applications for multiple indications including IBD and Multiple Sclerosis (MS) have been accepted for review by the National Medical Products Administration (NMPA) of China.

9MW5211 is the world's first clinical-stage drug candidate for its target. It is a highly specific, depleting, and innovative antibody independently developed by Mabwell, designed to precisely intervene in the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells act as the core driving factors in the occurrence and development of various autoimmune diseases. The target molecule of 9MW5211 is specifically expressed on the surface of pathogenic immune cells and serves as a vital biological marker of their abnormal activation. By selectively recognising and depleting this population of pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby delaying disease progression and ameliorating clinical symptoms.

Through multiple rounds of molecular engineering optimisation, 9MW5211 has demonstrated excellent target selectivity. While achieving efficient blockade, it significantly mitigates the risk of non-specific binding, ensuring deep depletion of pathogenic cells highly expressing the target protein. Such a unique mechanism of action is expected to not only bring deeper disease remission, but also potentially support an extended dosing interval, thereby enhancing patient compliance and quality of life.

Preclinical study results have demonstrated that 9MW5211 exhibits significant therapeutic potential in various mouse models of autoimmune diseases, suggesting its future clinical application may cover multiple major indications. Safety evaluations conducted in cynomolgus monkey models have shown a favorable safety profile. Clinical trial applications for other indications are also being actively advanced.